Navigation Links
Amgen Resolves G-CSF Patent Litigation With Teva
Date:7/15/2011

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen's patents relating to human G-CSF (granulocyte colony-stimulating factor) and methods for its use. Today's judgment was accompanied by Teva's admission that its Neutroval™ product infringes the two Amgen patents at issue in the litigation and that those patents are valid and enforceable.  The Court's injunction extends until Nov. 10, 2013, after which date Teva may sell Neutroval in the U.S.  Regarding Neugranin™, another Teva G-CSF product, Teva agrees not to sell Neugranin until Nov. 10, 2013 unless it first obtains a final court decision that Amgen's patents are not infringed by Neugranin. Pursuant to the parties' agreement, the launch date for either product could be sooner if certain unexpected events occur: a third party launches a similar G-CSF product and Amgen fails to sue that third party, or the patents are held invalid or unenforceable in a final court decision in an action brought by a third party. The settlement terms do not include any financial payments between the parties. The two patents at issue in the litigation, U.S. Patent Nos. 5,580,755 and 5,582,823, expire in early December 2013.

"We are very pleased with this outcome, as it reaffirms the validity of these important patents," said David J. Scott, senior vice president, general counsel and secretary at Amgen. "This closes this matter and allows Amgen to continue to focus on bringing innovative therapies to patients with grievous illnesses."

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

Contact: Amgen Thousand Oaks
Christine Regan: (805) 447-5476 (media)
Arvind Sood: (805) 447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
2. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
3. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
4. Amgen Announces Voting Results Of Annual Meeting of Stockholders
5. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
6. Amgen Oncology Data to be Presented at ASCO Annual Meeting
7. Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference
8. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
9. Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference
10. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
11. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the ... Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about ... in China. , The article by Zidor Aldama described the situation in which Chinese ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released a ... and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. ... she has risen above. , In “Memories,” readers get a firsthand look at what ...
(Date:7/24/2017)... Huntingdon Valley, PA (PRWEB) , ... July 24, 2017 , ... ... wind and rain storms wreak havoc across communities and often result in massive tree ... Top 3 actions homeowners can take now including tree trimming, tree cabling and hazardous ...
Breaking Medicine News(10 mins):